This advance brings surgeons one step closer to realizing the full value of intraoperative OCT...This is the first OCT system offering fully independent focus and zoom control for optimizing images from the cornea to the retina.
We are very excited to use the Bioptigen Envisu IntraSurgical OCT for its initial clinical assessments...The capability to deliver simultaneous OCT and surgical microscope images during DALK and DSAEK cornea transplant procedures addresses an important need in imaging-guided surgery for ophthalmology.
The light source emits different frequencies sequentially and is acquired at a very rapid speed. Also, the average wavelength is longer than SD-OCT. The premise is that you get deeper penetration into the tissue without the shadowing artifacts from overlying blood vessels like you do with SD-OCT.
The newest swept-source OCT has the advantage that the light source frequency sweep range and repetition rate can be adjusted to tailor the resolution, imaging range, and axial scan repetition rate for the specific imaging application.
This latest innovation from Bioptigen enables faster alignment, targeted explorations, and brilliant visualizations, while simultaneously viewing both OCT and color fundus images in real time...We expect this capability will be impactful not only for mouse and rat research, but also for handheld, dual-modality imaging of larger animals including cats, dogs, rabbits, and non-human primates," Buckland added. Bioptigen has begun producing and shipping the new multimodality systems from the company's North Carolina operations center, and will showcase the product at ARVO 2014 in Orlando, May 4-8.
This latest innovation from Bioptigen enables faster alignment, targeted explorations, and brilliant visualizations, while simultaneously viewing both OCT and color fundus images in real time
Currently available imaging equipment such as computer tomography or magnetic resonance tomography does not help us to analyse processes at the cell level like vascular deposits
It was a difficult decision but after numerous attempts by many dedicated people our ability to turn Imalux into an on-gong business was just not going to happen. The decision to cease operations is closely related to the significant financing challenges faced by early stage medical device companies in general and imaging companies specifically. It is unfortunate we closed the business but both current and past members of our team can be proud of all that was accomplished in trying to bring a new imaging technology to market. At some point there is little doubt our pioneering technology will be clinically adopted on a large scale in medicine. We thank our customers, investors and partners for their support and assistance over the years.
We are pleased to have this clearance, and confident the results reflect the quality of our diagnostic tools in imaging that assist doctors in diagnosing ocular diseases
